Glima Tablet 100 Milligrams (Imatinib Mesylate)

Adult dose

For adult patients with chronic myeloid leukemia (CML), a dose of 400mg to 600mg once daily is recommended. The recommended dose is 400mg for patients with Philadelphia chromosome-positive chronic-phase disease and 600mg for patients in the accelerated or blast phase. If necessary, the dose may be increased from 400mg to 600mg or from 600mg to 800mg (400mg twice daily). For adult patients with gastrointestinal stromal tumors (GIST), a dose of 400mg daily is recommended. The dose is 400mg daily for myelodysplastic/myeloproliferative diseases; for hypereosinophilic syndrome/chronic eosinophilic leukemia, the dose may be increased from 100mg to 400mg daily. For recurrent or metastatic dermatofibrosarcoma protuberans, take 800mg daily (400mg twice daily). Take with a meal and plenty of water. Take 400mg or 600mg once daily, and 800mg twice daily. Patients who cannot swallow the film-coated tablets may take them suspended in water or apple juice. Continue treatment until disease progression or unacceptable toxicity occurs. In patients with hepatic or renal impairment, start with at least 400mg daily and adjust the dose as needed. No special dose adjustment is required for elderly patients. If nonhematologic or hematologic adverse reactions occur, reduce the dose appropriately or interrupt treatment, then resume treatment.

Child dose

For pediatric patients with chronic myeloid leukemia, a dose of 340mg/m2 per day based on body surface area is recommended; the total daily dose should not exceed 600mg. The dose may be administered once daily or divided into two doses, in the morning and evening. For dose adjustment, the dose may be reduced from 340mg/m2 to 260mg/m2 or 200mg/m2 depending on nonhematologic or hematologic adverse reactions. If the film-coated tablets cannot be swallowed, take them suspended in water or apple juice.

This medication should not be used in patients with hypersensitivity to this drug or any of its components. Women who are pregnant or may become pregnant should not take this medication. Nursing mothers are also advised not to take this medication. Caution should be exercised when administering this medication to patients with impaired liver or kidney function, and regular monitoring is necessary. Patients with a history of heart disease or heart failure and renal failure should closely monitor heart function while taking this medication. Cardiac-related adverse reactions have rarely been reported in patients with hypereosinophilia syndrome; therefore, pre-treatment cardiac function testing is recommended, and steroid therapy may be considered as necessary. Patients taking levothyroxine after thyroid surgery should regularly check their thyroid function. In pediatric patients before puberty, this medication may cause growth retardation, so careful monitoring of growth status is necessary. Tumor lysis syndrome may occur, so it is recommended to correct any dehydration and treat elevated uric acid levels before administration. Patients who are carriers of the hepatitis B virus must test for infection before administration and closely monitor liver function and viral activity during treatment. During administration of this medication, side effects such as neutropenia, thrombocytopenia, anemia, headaches, dyspepsia, edema, weight gain, nausea, vomiting, muscle cramps, diarrhea, rashes, fatigue, and abdominal pain may frequently occur. If adverse reactions are severe, dose adjustment may be needed, and in rare cases, discontinuation of the medication may be necessary. It is important to periodically check patients' conditions and the occurrence of side effects during long-term use of this medication.

• Neutropenia
• thrombocytopenia
• anemia
• headache
• dyspepsia
• edema
• weight gain
• nausea
• vomiting
• muscle cramps

This medication is sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. Additionally, it should be kept at room temperature between 1 to 30 degrees Celsius, avoiding overly hot or cold conditions.

Appearance

Dense yellow to brown round film-coated tablet

Package unit

60 tablets (10 tablets/PTP X 6)